Clinical trials: NSCLC, Squamous or Non-Squamous
Non-squamous Non-small Cell Lung Cancer
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
This is an open label single group, Phase 2, 1-arm study for treatment to evaluate efficacy, safety, and Pharmacokinetic (PK) of tusamitamab ravtansine in nonsquamous non-small-cell-lung-cancer (NSQ NSCLC) participants with…
- Trial name
- CARMEN-LC06 (NCT05245071)
- Testing
- Tusamitamab ravtansine
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Sanofi
Non-Squamous Non-Small Cell Lung Cancer
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin…
- Trial name
- NCT00974584
- Testing
- GDC-0941, bevacizumab, carboplatin
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Non-small Cell Carcinoma, Adenocarcinoma of Lung
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
This 2-phase study will determine the safety of treating patients with non-small cell lung cancer with the genetically engineered HyperAcute-Lung cancer vaccine.
- Conditions
- Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma
- Trial name
- NCT00073398
- Testing
- Drug: Hyperacute Lung Cancer Cell Vaccine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- NewLink Genetics Corporation
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Non-small Cell Lung Cancer
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.
- Trial name
- CANOPY-1 (NCT03631199)
- Testing
- canakinumab, pembrolizumab, carboplatin
- Where
- 152 sites in United States, Argentina and 39 more
- Volunteers
- 673 people
- Sponsor
- Novartis Pharmaceuticals
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.
- Trial name
- NCT02087241
- Testing
- AZD1775, pemetrexed, carboplatin
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage…
- Trial name
- NCT03663205
- Testing
- Tislelizumab, Cisplatin, Carboplatin
- Where
- 47 sites in China
- Volunteers
- 334 people
- Sponsor
- BeiGene
Non-Small Cell Lung Cancer
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line…
- Trial name
- NCT05654454
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 28 sites in Russia
- Volunteers
- 620 people
- Sponsor
- Mabscale, LLC
Non-small Cell Lung Cancer
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.
- Trial name
- NCT02093962
- Testing
- TH-302 combination with pemetrexed
- Where
- 80 sites in United States, Czechia and 8 more
- Volunteers
- 265 people
- Sponsor
- ImmunoGenesis
Non-small Cell Lung Cancer (NSCLC)
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
The purpose was to evaluate the efficacy and safety of the combination of capmatinib with pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with locally advanced or metastatic NSCLC who have PD-L1…
- Trial name
- NCT04139317
- Testing
- Capmatinib, Pembrolizumab
- Where
- 36 sites in Australia, Belgium and 14 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002550
- Testing
- cisplatin, etoposide, conventional surgery
- Where
- 16 sites in United States, South Africa
- Volunteers
- 429 people
- Sponsor
- Radiation Therapy Oncology Group
Carcinoma, Non-Small-Cell Lung
Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
A phase II study to assess the efficacy and safety of Fruquintinib Combined With Sintilimab and Chemotherapy as a first-line treatment in patients with unresectable or metastatic advanced Wild-type Genotype non-squamous Non-small…
- Trial name
- NCT04956146
- Testing
- Fruquintinib，Sintilimab，Pemetrexed，Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
NSCLC, HNSCC
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
- Trial name
- TACTI-002 (NCT03625323)
- Testing
- eftilagimod alpha, pembrolizumab (KEYTRUDA®)
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Immutep S.A.S.
Lung, Carcinoma
Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) tyrosine kinase is one of most popular target molecules in the field of anticancer drug research.
- Trial name
- NCT02139579
- Testing
- Bevacizumab
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960…
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04628780
- Testing
- PF-07209960
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
This phase II clinical trial studies how well combining different regimens of chemotherapy and gefitinib with radiation therapy work in treating patients with stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00040794
- Testing
- paclitaxel, carboplatin, gefitinib
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
This study is an open-label, randomized, controlled, multicenter Phase IIIb clinical study, aiming to evaluate the efficacy, safety, and tolerability of Vebreltinib Enteric Capsule combined with platinum-based doublet…
- Trial name
- KUNPENG-3 (NCT06930794)
- Testing
- Vebreltinib combined with platinum-based doublet chemotherapy., platinum-based doublet chemotherapy.
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
This phase II trial is studying the side effects and how well giving radiation therapy together with bevacizumab, paclitaxel, and carboplatin works in treating patients with unresectable stage IIIB or stage IV non-small cell lung…
- Conditions
- Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, Hemoptysis, Squamous Cell Lung Cancer
- Trial name
- NCT00387374
- Testing
- bevacizumab, paclitaxel, carboplatin
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer